Skip to content

Developing Combination Therapies in Type 1 Diabetes

Deadlines are 5:00 PM (Eastern). No extensions will be granted.

Milestone Date Status
Letter of Intent Required Nov 17, 2021 Passed
Application Jan 31, 2022 Passed
Award Notification May 31, 2022 Passed
Earliest Start Jul 31, 2022 Passed

Background & Purpose

Please click on the “RFA Announcement” link for complete information.


JDRF, the world’s leading non-profit organization with the mission to cure type 1 diabetes (T1D), invites letters of intent (LOI’s) for the preclinical and clinical development of combination therapies to improve on the previous evidence of safety and efficacy of monotherapy approaches in the setting of T1D.

Successes across multiple aspects of autoimmune disease modifying therapies have brought the field to a unique place that will benefit from coordination, integration, and harmonization of efforts both in the preclinical and clinical settings for drug development. JDRF has an unprecedented opportunity to achieve progress in assessment of increased therapeutic effectiveness and reduced toxicity offered by pairing of single agents as combination therapies. T1D is a complex disease, suggesting that multipronged therapeutic approaches might be needed to improve clinical outcomes. To that end, proposals will be considered that combine agents with different modes of action and targets, such as those that modulate immune responses, improve metabolic status, and/or improve/protect beta cell function. To be considered, projects proposed should have goals that align with the JDRF Cures Program aims of delaying, halting, or reversing the onset of T1D, as outlined in the JDRF Research Strategy for Disease Modifying Therapies (available for review here).